UBX News and Press, Unity Biotechnology Inc. From 05/25/22

SOUTH SAN FRANCISCO, Calif., May 25, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (Nasdaq: UBX), a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that members of its senior management team will provide a corporate update and ...

-Completed enrollment in BEHOLD, the Phase 2 clinical trial of UBX1325 in DME; BEHOLD remains on track with 12-week safety and efficacy data anticipated by mid-year 2022- -Dosed first patient in ENVISION, the Phase 2 clinical trial of UBX1325 in wet age-related macular degenerat...

SOUTH SAN FRANCISCO, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, announced presentations at the Association for Research in Vision and O...

SOUTH SAN FRANCISCO, Calif., April 21, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that clinical data results from the Phase 1 study of ...

UNITY Biotechnology (NASDAQ:UBX) on Tuesday dosed the first patient in its phase 2 clinical trial of its investigational small molecule inhibitor UBX1325 in subjects with wet age-related macular degeneration (wAMD), a chronic eye disorder that causes blurred vision or a blind spot in the visu...

SOUTH SAN FRANCISCO, Calif., April 19, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that the first patient has been dosed in the ENVISION...

12-week safety and efficacy data anticipated by mid-year 2022 24-week safety and efficacy data anticipated before year-end 2022 SOUTH SAN FRANCISCO, Calif., April 12, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology ...

Gainers: ORIC Pharmaceuticals (ORIC) +14%. Unity Biotechnology (UBX) +13%. Applied Therapeutics (APLT) +11%. Genetron (GTH) +11%. Clarus Therapeutics (CRXT) +8%. Losers: SELLAS Life Sciences SLS -39%. Pulse Biosciences (PLSE) -22%. Spero Therapeutics SPRO&#x...

Unity Biotechnology (NASDAQ:UBX) has filed for a $125M mixed shelf offering. Shares are up 19% in after-hours trading. The filing does not necessarily indicate that a sale has begun, or will occur in the future. The company said it will explain the use of proceeds in a prospect...

Unity Biotechnology press release (NASDAQ:UBX): Q4 GAAP EPS of -$0.18 beats by $0.18. Revenue of $4.78M. Cash, cash equivalents and marketable securities totaled $90.1 million as of December 31, 2021 compared with $115.6 million as of December 31, 2020 For further details see: Unity Bio...